ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment whi...
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy. Founded in 1923, ALK has devoted decades of research and development to improve quality of life for the many allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication, by developing products that provide long-lasting relief. ALK offers allergy immunotherapy products in the form of injections, sublingual drops and sublingual tablets – the latter is the newest, most documented and most convenient form of treatment. In addition, ALK also produces an adrenaline auto-injector for the treatment of severe allergic reactions (anaphylaxis) and also manufactures products used in the diagnosis of allergies. The company has approximately 2,000 employees, with subsidiaries, production facilities and distributors worldwide. ALK is headquartered in Denmark and listed on NASDAQ Copenhagen (OMX: ALK B). Read more about ALK at www.alk.net